Microba has backed sufferers of IBD through a donation to support IBD organisation Crohn’s and Colitis Australia.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Improved therapies for the long-term management of IBD are crucial and a currently unmet clinical need.
Microba has received a significant investment from global precision medicine company, Macrogen.
Microba will join forces with other internationally-renowned research entities on a groundbreaking project to tackle antimicrobial resistance.
Microba has partnered with Macrogen to develop new microbiome services in offshore markets.
Microba has been named ‘Emerging Company of the Year’ in the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards.
Cloud infrastructure will be used to bolster Microba’s advanced gut microbiome research.